5^th International Conference and Exhibition on Metabolomics May 16-18, 2016 Osaka, Japan

Maurizio Ferrari, (M.D.), is Full Professor of Clinical Pathology, University Vita-Salute San Raffaele, Director of Clinical Molecular Biology and Cytogenetics Laboratory, and Head of Genomic Unit for the Diagnosis of Human Pathologies, Division of Genetics and Cell Biology, IRCCS San Raffaele, Milan, Italy. He received his Degree in Medicine at the Milan University, is Specialized in Pediatrics, Haematology and Medical Genetics. He was Post-doc at Hospital Paul Brousse, Villejuif, Paris and Honorary Registrar in Haematology at UCH, London. He was Scientific Coordinator of Clinical Research, IRCCS H San Raffaele, Milan (1996-1999), Chairman of Committee on Clinical Molecular Biology Curriculum of IFCC (2002-2007), member of the Education and Management Division of IFCC (2008-2011). He was Chairman of the Education and Management Division of IFCC (2012-2014), member of IFCC Task Force on Pharmacogenetics (from 2008), advisor of CLSI Committee on Molecular Methods. He is Dean of Master Degree in Molecular and Cellular Medical Biotechnology (2008 at present) and President of the European Society of Predictive Medicine (2009 at present). He received in 2004 the IFCC-Abbott Award for Significant Contributions in Molecular Diagnostics. He is author of 849 publications: peer reviewed journals: 246, other journals: 67, book: 1, chapter\\\'s book: 45 and 490 abstracts at International and National Congress. Total I.F. 1113,83; h-index:42 (scholar Google); citations: 8846; i-10 index:131.

His scientific interests are oriented mainly on molecular diagnostic methods, nucleic acid circulating in maternal plasma, molecular studies of several genetic pathologies. He developed methods for DNA analysis as multiplex PCR and capillary electrophoresis also in a temporal thermal gradient, set up a method involving the ligase chain reaction (LCR) and developed a new method known as double-gradient DGGE (DG-DGGE) for the identification of unknown mutations. In the last 4-5 years he has focused his research activity on the detection of foetal DNA in maternal plasma for non-invasive prenatal diagnosis and for diagnostic application in the genetic and oncology field. At present, his research is focused on the development of diagnostic tests with the application of the next generation sequencing.

Choon Nam ONG is the Director of the NUS Environmental Research Institute (NERI) and a professor at the Saw Swee Hock School of Public Health, National University of Singapore. He has published more than 300 papers in international peer-reviewed journals with an h-index of 75, and over 17,000 citations. His main research interest is Environmental Health Sciences and teaches in Toxicology and Environment Health, and nursing a lifelong passion of all matters related to environment on health. Since 1985, he has served as a consultant to the World Health Organization (WHO) on many occasions and was involved in 12 of its Health Criteria publications.He is an editorial board member of several international journals on environment and sustainability. He is a visiting professor to several overseas universities and serves as a Scientific Advisor to the China Center of Disease Control and Prevention (CDC). He was the recipient of Astra-Zeneca American Toxicology Society Award, 2002. Dr Ong also served as an advisor to the OECD, US National Water Research Institute, and has been consulted often by international health agencies on issues related to environmental health. He has been a member of the WHO Guidelines for Drinking Water Quality Expert Panel since 2003. His research group currently focuses on the use of metabolomics as a technology platform for biomedical and environmental research.

Environmental Health, Metabolomics, Toxicology

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Metabolomics, Mass Spectrometer, HPLC

Bjoern Riefke, Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma After the study of Biology and his PhD in Zoology/Animal Physiology at the Heinrich-Heine-University in Duesseldorf, Germany Bjoern Riefke started to work as a research fellow in 1994 at the Institute of Diagnostic Research in Berlin. His main research field was the biological characterization of dyes for near-infrared in-vivo imaging. In 1998 he followed an offer of Schering AG to lead a research group at Justesa Imagen S.A. in Madrid, Spain as assistant manager and head of biological research and development in the field of X-ray contrast media research. In 2003 he moved back to Bayer Health Care Berlin (former Schering AG) and headed the group of early and mechanistic toxicology with research support for the early detection of safety liabilities of drug candidates and one year later headed the group of clinical pathology with the establishment of metabolic profiling technology in toxicology. Since 2005 he participated in the validation of new biomarkers within the HESI Nephrotoxicity Working Group. Beside the routine support and project related work the main area of interest are the application of metabolic profiling in toxicology and in pharmacological studies and the evaluation of new biomarkers for different organ toxicities in comparison to traditional endpoints of clinical pathology and histopathology in the context of toxicology testing.

Metabolic Profiling and Clinical Pathology

Dr. Yoshiro Fujii is a director and chief dentist of Shin Kobe Dental Clinic. 1985:D.D.S. (Certified by Japanese Health Ministry).1989: He received Koide prize. Finished graduate school, Nagoya, Japan. and Ph.D (Aich Gakuin University Graduate school, Nagoya). 2000: Dr. Fujii began to run Shin Kobe Dental Clinic (Kobe, Japan). 2009: Fellow of the international college of acupuncture and electro-therapeutics (F.I.C.A.E). 2013,2014: 100 next era CEOs in Asia (Japan times). 2014: Editioriall board member of Savvy Science Publisher. 2015: Editorial board member of British Journal of Medical Research.. 2015: 100 Next-era Leaders in Asia (Japan times). He has written five published works in Japanese and two in English. He is an Authorization doctor of the Japan Bi-Digital O-Ring Test. Association and a director of the Japan Society of Dental Equipment. He published eleven international academic articles in English. 2014-15: He was a chair or co-chair three times in various international congresses.

Holistic Dentistry

Scott Tebbutt is Associate Professor in the Department of Medicine, Division of Respiratory Medicine, University of British Columbia, and Principal Investigator at the James Hogg Research Centre, Institute for Heart + Lung Health, St. Paul’s Hospital, Vancouver, Canada. Since 2006, he has served as Co-Director of the Molecular Phenotyping and Genotyping Core of the James Hogg Research Centre, and he is currently Director of the Technology Development Core. He is also Chief Scientific Officer of the Prevention of Organ Failure (PROOF) Centre of Excellence, focused on heart, lung and kidney failure. Dr. Tebbutt earned his B.A. degree in Biochemistry from the University of Oxford (Oriel College), England in 1989, and his Ph.D. in Molecular Genetics from the University of East Anglia in 1993 (supervised by Dr. David Lonsdale, Cambridge Laboratory, John Innes Centre, England). He pursued post-doctoral fellowships in the laboratories of Professor Ann Harris (University of Oxford, Institute of Molecular Medicine) and Professor Diana Hill (University of Otago, Dunedin, New Zealand), where he studied the molecular genetics of cystic fibrosis. He was appointed Research Fellow at the University of Otago (1995-2001), leading a research team investigating the genomics of the sheep cystic fibrosis locus. He was seconded to a start-up biotechnology company (Global Technologies (NZ) Ltd.) as Director of Genomics (1999-2001). He moved to Canada in 2001, and was Senior Researcher in the Centre for Biomedical Research (University of Victoria, 2001-2002), prior to being recruited to the James Hogg Research Centre (formerly the iCAPTURE Centre) at St. Paul’s Hospital, Vancouver (2002).

Dr. Tebbutt’s research programme is focused on the genomics of complex respiratory disease, including the early and late reactions in allergic asthma and rhinitis. He also leads a multidisciplinary collaboration to investigate interactions between fungal spores and human airway cells. His research combines hypothesis-driven study of biological mechanisms with the development of advanced tools and technology (including bioinformatics and microfluidics-based systems) to better facilitate basic and translational research. Dr. Tebbutt has published original research contributions in journals such as the Proceedings of the National Academy of Sciences (U.S.A.), Journal of Medical Genetics, Genomics, BioTechniques, Bioinformatics, BMC Bioinformatics, BMC Medical Genomics and PLoS ONE. He has published numerous technical reviews as well as book chapters on the role of genetic variation in respiratory disease. He has served as reviewer on several grant panels, including the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research, and he is Associate Editor for the journal BMC Genetics. Dr. Tebbutt has received several fellowships and awards, including an Edward Penley Abraham Research Trust Fellowship (U.K.), a Journal of Cell Science Traveling Fellowship Award, and a Research Fellowship from the Cystic Fibrosis Association of New Zealand. He has been awarded competitive research funding from organizations such as the National Sanitarium Association (Canada), the British Columbia Lung Association, AllerGen NCE Inc. (Allergy, Genes and Environment Network), the Canadian Institutes of Health Research, the BC Proteomics Network, and the Wellcome Trust (U.K.).

Houkai Li has completed his PhD at the age of 32 years from Shanghai Jiao Tong University and Postdoctoral studies from University of North Carolina (2011.8-2013.5) and Chinese Academy Sciences (2008.11-2011.3) respectively. He is now a Professor at Center for Traditional Chinese Medicine and Systems Biology in Shanghai University of Traditional Chinese Medicine. He has published over 22 papers in reputed journals.

Metabolomics and Molecular biology

Jagat Kanwar is an Associate Professor of Immunology & Cell Biology, and Group Leader in “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” at Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells.

Cancer and chronic inflammatory diseases targeted nanomedicine based drug delivery siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation Drug discovery with anticancer targets for cancer cell survival, death, arrest, and repair Development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection Development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers Development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers Development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging Novel nano-medicinal based vaccines and immunotherapy Micro-fluidics and Lab-on-a-Chip devices for delivery and diagnosis

Professor Sam Li is a faculty member at the Department of Chemistry, National University of Singapore (NUS). He received his BSc, PhD and DSc degrees from Imperial College, UK. His research interests include environmental science and technology, metabolomics, biosensors and nanotechnology. He has authored/co-authored 325 publications in international peer review journals, more than 100 conference presentations and 10 US patents. He serves/served on editorial advisory boards of several international scientific journals, including Electrophoresis (Germany), Journal of Chromatographic Science (USA), LC-GC (Asia Pacific), and Biomedical Chromatography (UK).

Environmental science and technology, Metabolomics, Biosensors and Nanotechnology

Thomas W. Chittenden is a Theoretical Systems Biologist and Founder of the Complex Biological Systems Alliance, a global scientific think tank dedicated to furthering scientific understanding of biological complexity and the nature and origins of human disease. Tom serves as a Senior Biostatistician and Mathematical Biologist for the Research Computing Group at the Harvard Medical School and a Scientific Advisor for the Pathway Genomics Corporation. He is a Research Fellow at the Vertex Society, an Associate Member of the International Society for Philosophical Enquiry, and a Member of the New England Complex Systems Institute. Tom holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Biology and Bioinformatics from the University of Oxford. His multidisciplinary postdoctoral training includes experimental investigations in Molecular and Cellular Cardiology at the Dartmouth Medical School and Integrative Functional Genomics at the Dana-Farber Cancer Institute and the Harvard School of Public Health.

A major focus of Tom’s research involves development and application of integrated systems biology models to investigate evolutionary factors of human disease. His overall objective is to understand how genetic variation and somatic mutation regulate aberrant gene activity and subsequent disease biology. To this end, Tom spent a year as a Visiting Research Scientist in the Department of Statistics at the University of Oxford, where he formulated a general strategy for constructing prediction models by integrating a priori biological knowledge with multiple types of high-throughput genomic data. This approach improves performance of established classification methods via enhanced semantic interoperability for mapping between multiple biomedical ontologies and the subsequent identification of genes more highly predictive of disease etiology.

Dr. Vladimir E. Bondarenko is Associate Professor at Georgia State University, USA. He did his Ph.D. Physics and Mathematics, Moscow State University, Russia, 1990. Dr. Bondarenko’s research interests include dynamical systems, neuronal and cardiac cell models, neural networks, models of cardiac arrhythmias, ion channel models.

Dynamical systems, Neuronal and Cardiac cell models, Neural networks, Models of cardiac arrhythmias, Ion channel models.

Michel Aliani is an Associate Professor at the Department of Human Nutritional Sciences at the University of Manitoba and a member of the Canadian Centre for Agri-Food Research in Health and Medicine in Winnipeg, Manitoba. He was educated in France (B.Sc. and Engineering degree in Agri-Food Biochemistry) and in Northern Ireland (PhD, and Post-doctoral at Queen’s University Belfast) prior to move to University of Manitoba in 2007. His area of scientific expertise includes food science, mass spectrometry and metabolomics.

The focus of Dr. Aliani’s research is therefore twofold. 1.To provide the scientific and molecular basis for the development and successful marketing of functional foods targeted to patients as well as healthy populations in the world and 2.To investigate the effect of active compounds on metabolic pathways in animal and human model.

Dr. Deliang Guo is Assistant Professor at Ohio State University Comprehensive Cancer Center. His major research interests are tumor metabolism, autophagy and oncogenic signaling. His research is supported by multiple grants from NIH, American Cancer Society and American Brain Tumor Association.

Tumor metabolism, Autophagy and Oncogenic signaling